Group B Streptococcus Vaccine in Healthy Females (MVX0002)

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel®) in Healthy Female Subjects Aged 18 to 40

A Phase I, randomised, single centre, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine.

Study Overview

• Status: Completed
• Conditions: Group B Strep Infection
• Intervention / Treatment: Biological: GBS-NN/NN2 with Alhydrogel® 25; Biological: Placebo GBS-NN/NN2 with Alhydrogel® 25; Biological: GBS-NN/NN2 with Alhydrogel® 50; Biological: Placebo GBS-NN/NN2 with Alhydrogel® 50

Detailed Description

There will be 4 arms in 2 cohorts of 30 subjects. Cohort 1 will receive two 0.5 mL injections, 4 weeks apart, each consisting of 25 μg of GBS-NN and 25 μg of GBS-NN2 (24 subjects) or placebo (6 subjects). Cohort 2 (30 subjects) will receive two 0.5 mL injections, 4 weeks apart, each consisting of 50 μg of GBS-NN and 50 μg of GBS-NN2 (24 subjects) or placebo (6 Subjects). All vaccines will be adsorbed to 500 μg Al3+ as Alhydrogel®.

Safety will be assessed after all subjects have completed Visit 4 (Day 8) for Cohort 1, at which point the decision will be made as to whether proceeding with administration of the doses in cohort 2 is appropriate.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Wales
    • Merthyr Tydfil, Wales, United Kingdom, CF48 4DR
      • Simbec Research Limited

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Healthy female subjects aged 18 - 40 years.
2. Body mass index (BMI) ≥18 and ≤30 kg/m2.
3. Subjects weight ≥50kg and ≤100kg at screening.
4. Able to voluntarily provide written informed consent to participate in the study.
5. Subjects are pre-menopausal.

6. Females of childbearing potential must have a negative pregnancy test at screening (β HCG) and prior to each dose. To prevent pregnancy female subjects of childbearing potential must take adequate contraceptive precautions for the entire duration of study participation (up to Day 85). Adequate and highly effective contraceptive precautions include:

   • Established use of oral, injected or implanted hormonal methods of contraception.
   • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
   • Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
   • Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female subjects, the vasectomised male partner should be the sole partner for that subject].
   • True abstinence, when this is in line with the preferred and usual lifestyle of the subject.

   [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].

   • The chosen contraception method(s) must be followed from the first dose until at least Day 85 of the study.

7. Non-smokers for at least 3 months prior to first study vaccine administration.

Exclusion Criteria:

1. Subjects who have received GBS-NN vaccine previously.
2. Subjects with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.
3. Pregnant or lactating females.
4. Laboratory values at screening which are deemed by the investigator to be clinically significantly abnormal.
5. Positive drug screen for drugs of abuse or a positive alcohol urine test prior to first dosing unless there is a documented medical explanation for the positive result other than drugs of abuse (e.g., the subject has been prescribed opioids for pain).
6. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
7. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
8. Any significant illness during the 4 weeks preceding check-in for this study (Day 1).
9. Subjects with a history of allergic reactions after previous vaccination.
10. Subjects who have received any vaccine within 30 days of screening, or who are planning to receive a vaccine up to Day 85 of the study.
11. Subjects receiving immunosuppressive therapy in the 6 months prior to screening, taking any short-term medications including over-the-counter (OTC) preparations, within 7 days of the first dose. Chronic medications such as antihypertensives, bronchodilators, oral contraceptives or statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the Investigator. Paracetamol will be permitted for the treatment of headache or other symptoms. Use of OTC vitamins and dietary supplements is allowed
12. Subjects with tattoos at the proposed site of vaccine administration.
13. Donation of blood or blood products within 90 days prior to vaccine administration or intending to donate blood or blood products within 90 days of the last visit.
14. Subjects who, in the opinion of the Investigator, are unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: GBS-NN/NN2 with Alhydrogel® 25; GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart	Biological: GBS-NN/NN2 with Alhydrogel® 25; GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
PLACEBO_COMPARATOR: Placebo GBS-NN/NN2 with Alhydrogel® 25; Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart	Biological: Placebo GBS-NN/NN2 with Alhydrogel® 25; GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
EXPERIMENTAL: GBS-NN/NN2 with Alhydrogel® 50; Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart	Biological: GBS-NN/NN2 with Alhydrogel® 50; GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
PLACEBO_COMPARATOR: Placebo GBS-NN/NN2 with Alhydrogel® 50; Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart	Biological: Placebo GBS-NN/NN2 with Alhydrogel® 50; GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment Emergent Adverse Events	Number of Participants with Treatment Emergent Adverse Events	85 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunoglobulin(Ig)G Antibody Concentration	Adjusted geometric mean concentration (GMC)	Day 85
Fold Change in Antibody Concentration	Geometric mean fold change in antibody concentration from Day 1 to Day 85 for each group.	Day 1 to Day 85
Seroconversion Rate	4-fold increase in Immunoglobulin(Ig)G antibody concentration	Day 85
Number of Participants With an Immune Response to First and Second Doses	Number of participants with Immunoglobulin(Ig)G antibody concentration above thresholds	Day 29 and Day 85

Collaborators and Investigators

• Sponsor: Minervax ApS
• Collaborators: Simbec Research

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 9, 2019
• Primary Completion (ACTUAL): October 14, 2019
• Study Completion (ACTUAL): May 7, 2020

Study Registration Dates

• First Submitted: January 9, 2019
• First Submitted That Met QC Criteria: January 15, 2019
• First Posted (ACTUAL): January 16, 2019

Study Record Updates

• Last Update Posted (ACTUAL): February 2, 2021
• Last Update Submitted That Met QC Criteria: January 30, 2021
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Streptococcal Infections; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Immunologic Factors; Gastrointestinal Agents; Adjuvants, Immunologic; Antacids; Aluminum Hydroxide
• Other Study ID Numbers: 2017-003871-27

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No